Seek & Destroy, use of targeting peptides for cancer detection and drug delivery

Show full item record



Permalink

http://hdl.handle.net/10138/236104

Citation

Le Joncour , V & Laakkonen , P 2018 , ' Seek & Destroy, use of targeting peptides for cancer detection and drug delivery ' , Bioorganic & Medicinal Chemistry , vol. 26 , no. 10 , pp. 2797-2806 . https://doi.org/10.1016/j.bmc.2017.08.052

Title: Seek & Destroy, use of targeting peptides for cancer detection and drug delivery
Author: Le Joncour, Vadim; Laakkonen, Pirjo
Other contributor: University of Helsinki, Research Programs Unit
University of Helsinki, Helsinki Institute of Life Science HiLIFE, Infra




Date: 2018-06-01
Language: eng
Number of pages: 10
Belongs to series: Bioorganic & Medicinal Chemistry
ISSN: 0968-0896
DOI: https://doi.org/10.1016/j.bmc.2017.08.052
URI: http://hdl.handle.net/10138/236104
Abstract: Accounting for 16 million new cases and 9 million deaths annually, cancer leaves a great number of patients helpless. It is a complex disease and still a major challenge for the scientific and medical communities. The efficacy of conventional chemotherapies is often poor and patients suffer from off-target effects. Each neoplasm exhibits molecular signatures - sometimes in a patient specific manner -that may completely differ from the organ of origin, may be expressed in markedly higher amounts and/ or in different location compared to the normal tissue. Although adding layers of complexity in the understanding of cancer biology, this cancer-specific signature provides an opportunity to develop targeting agents for early detection, diagnosis, and therapeutics. Chimeric antibodies, recombinant proteins or synthetic polypeptides have emerged as excellent candidates for specific homing to peripheral and central nervous system cancers. Specifically, peptide ligands benefit from their small size, easy and affordable production, high specificity, and remarkable flexibility regarding their sequence and conjugation possibilities. Coupled to imaging agents, chemotherapies and/or nanocarriers they have shown to increase the on-site delivery, thus allowing better tumor mass contouring in imaging and increased efficacy of the chemotherapies associated with reduced adverse effects. Therefore, some of the peptides alone or in combination have been tested in clinical trials to treat patients. Peptides have been well-tolerated and shown absence of toxicity. This review aims to offer a view on tumor targeting peptides that are either derived from natural peptide ligands or identified using phage display screening. We also include examples of peptides targeting the high-grade malignant tumors of the central nervous system as an example of the complex therapeutic management due to the tumor's location. Peptide vaccines are outside of the scope of this review. (C) 2017 The Authors. Published by Elsevier Ltd.
Subject: Cancer
Targeting peptide
Imaging
Phage display
Delivery
POSITRON-EMISSION-TOMOGRAPHY
TUMOR-HOMING PEPTIDE
NEWLY-DIAGNOSED GLIOBLASTOMA
BRAIN-BARRIER DISRUPTION
IN-VIVO
BREAST-CANCER
PROSTATE-CANCER
PHAGE-DISPLAY
EXTRACELLULAR-MATRIX
VASCULOGENIC MIMICRY
3111 Biomedicine
3122 Cancers
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0968089617311094_main.pdf 1.815Mb PDF View/Open
1_s2.0_S0968089617311094_main.pdf 1.815Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record